About syndax pharmaceuticals - SNDX
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.
SNDX At a Glance
Syndax Pharmaceuticals, Inc.
730 Third Avenue
New York, New York 10017
| Phone | 1-781-419-1400 | Revenue | 23.68M | |
| Industry | Biotechnology | Net Income | -318,758,000.00 | |
| Sector | Health Technology | Employees | 270 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
SNDX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 47.801 |
| Price to Book Ratio | 3.932 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.664 |
| Enterprise Value to Sales | 38.209 |
| Total Debt to Enterprise Value | 0.382 |
SNDX Efficiency
| Revenue/Employee | 87,703.704 |
| Income Per Employee | -1,180,585.185 |
| Receivables Turnover | 1.707 |
| Total Asset Turnover | 0.035 |
SNDX Liquidity
| Current Ratio | 5.824 |
| Quick Ratio | 5.82 |
| Cash Ratio | 5.532 |
SNDX Profitability
| Gross Margin | 96.478 |
| Operating Margin | -1,434.426 |
| Pretax Margin | -1,346.106 |
| Net Margin | -1,346.106 |
| Return on Assets | -47.658 |
| Return on Equity | -75.686 |
| Return on Total Capital | -50.288 |
| Return on Invested Capital | -54.208 |
SNDX Capital Structure
| Total Debt to Total Equity | 119.997 |
| Total Debt to Total Capital | 54.545 |
| Total Debt to Total Assets | 47.70 |
| Long-Term Debt to Equity | 115.625 |
| Long-Term Debt to Total Capital | 52.558 |